AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26324362 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (oxaliplatin 130 mg/m² on day 1 and capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks for 6 months)
Number of subjects: 1886
Study 26324362 — intervention group
Group type: COMPARATOR
Intervention: FU/FA (bolus fluorouracil/folinic acid for 6 months)
Number of subjects: 1886
Study 26324362 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 1886
Study 26324362 — intervention group
Group type: COMPARATOR
Intervention: FU/FA
Number of subjects: 1886
Study 23799929 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nerve stimulation (SQS) plus optimized medical management
Number of subjects: 400
Study 23799929 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical management (OMM) alone
Number of subjects: 400
Study 20466200 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (2 x 1,200 mg/day for 48 h)
Number of subjects: 251
Study 20466200 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus optimal hydration
Number of subjects: 251
Study 18419497 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned treatment interruption with nevirapine
Number of subjects: 35
Study 18419497 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned treatment interruption with efavirenz
Number of subjects: 35
Study 18419497 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (control group)
Number of subjects: 35
Study 17206976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of atosiban
Number of subjects: 0
Study 17206976 — intervention group
Group type: COMPARATOR
Intervention: Standard administration of atosiban
Number of subjects: 0
Study 17206976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atosiban administration
Number of subjects: 0
Study 17206976 — intervention group
Group type: COMPARATOR
Intervention: Standard atosiban administration
Number of subjects: 0
Study 12545081 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/IDV (100/400 mg bid)
Number of subjects: 20
Study 12545081 — intervention group
Group type: COMPARATOR
Intervention: IDV (800 mg tid)
Number of subjects: 20
Study 10767070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective navigator-echo respiratory gating (NE)
Number of subjects: 24
Study 10767070 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold imaging (BH)
Number of subjects: 24
Study 8781321 — intervention group
Group type: EXPERIMENTAL
Intervention: 520-kcal diet with less than 2 g fat/d
Number of subjects: 13
Study 8781321 — intervention group
Group type: COMPARATOR
Intervention: 900-kcal diet with 30 g fat/d (including one 10-g fat meal)
Number of subjects: 13
Study 1596317 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Methylprednisolone
Number of subjects: 51
Study 1596317 — intervention group
Group type: COMPARATOR
Intervention: 10 ml NaCl 0.9%
Number of subjects: 51
Study 3156544 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6mg/kg
Number of subjects: 51
Study 3156544 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium 0.25mg/kg
Number of subjects: 51
Study 29468670 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based rapid rehousing
Number of subjects: 172
Study 29468670 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent subsidy
Number of subjects: 172
Study 29468670 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 172
Study 29352007 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 14793
Study 29352007 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14793
Study 27501833 — intervention group
Group type: EXPERIMENTAL
Intervention: D6 (heel-to-toe drop of 6 mm)
Number of subjects: 553
Study 27501833 — intervention group
Group type: EXPERIMENTAL
Intervention: D0 (heel-to-toe drop of 0 mm)
Number of subjects: 553
Study 27501833 — intervention group
Group type: EXPERIMENTAL
Intervention: D6 and D0 (low-drop shoes) in occasional runners
Number of subjects: 553
Study 25275230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous jejunal infusion of levodopa-carbidopa intestinal gel
Number of subjects: 0
Study 25275230 — intervention group
Group type: COMPARATOR
Intervention: Standard oral levodopa therapy
Number of subjects: 0
Study 23207562 — intervention group
Group type: COMPARATOR
Intervention: Normal saline wrapping (Group I, N=10)
Number of subjects: 41
Study 23207562 — intervention group
Group type: EXPERIMENTAL
Intervention: NG solution wrapping (Group II, N=11)
Number of subjects: 41
Study 23207562 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cc NG injection (Group III, N=10)
Number of subjects: 41
Study 23207562 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (Group IV, N=10)
Number of subjects: 41
Study 20485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colorectal resection
Number of subjects: 52
Study 20485146 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 52
Study 18588611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin alone
Number of subjects: 150
Study 18588611 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus oxytocin
Number of subjects: 150
Study 15752663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg once a day from day 5 to day 25)
Number of subjects: 20
Study 15752663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg once a day from day 8 to day 25)
Number of subjects: 20
Study 15752663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (both groups)
Number of subjects: 20
Study 12228784 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin plus ASA
Number of subjects: 525
Study 12228784 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) plus ASA
Number of subjects: 525
Study 9477058 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial neuromuscular block with vecuronium (mean TOF ratio 50%)
Number of subjects: 6
Study 9477058 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing through a resistor
Number of subjects: 6
Study 9477058 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 5% carbon dioxide
Number of subjects: 6
Study 9477058 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing with inspiratory resistor
Number of subjects: 6
Study 7605013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 21
Study 7605013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 21
Study 7605013 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control intervention mentioned)
Number of subjects: 21
Study 1978689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP), up to 6 g/day, administered for 25-35 days
Number of subjects: 20
Study 1978689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 686893 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral neomycin and erythromycin base
Number of subjects: 0
Study 686893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31673828 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic peritoneal dialysis with concurrent colostomy
Number of subjects: 20
Study 31673828 — intervention group
Group type: COMPARATOR
Intervention: Control group (children on chronic peritoneal dialysis without colostomy)
Number of subjects: 20
Study 31070699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleretinal screening (TR)
Number of subjects: 801
Study 31070699 — intervention group
Group type: COMPARATOR
Intervention: Universal referral (UR)
Number of subjects: 801
Study 25603481 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation pressure at 150 cm (Group 3)
Number of subjects: 168
Study 25603481 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation pressure at 100 cm (Group 2)
Number of subjects: 168
Study 25603481 — intervention group
Group type: COMPARATOR
Intervention: Irrigation pressure at 80 cm (Group 1)
Number of subjects: 168
Study 24938534 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) 200 or 285 μg/day
Number of subjects: 69
Study 24938534 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) high-dose
Number of subjects: 69
Study 24938534 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SY) low-dose
Number of subjects: 69
Study 24938534 — intervention group
Group type: COMPARATOR
Intervention: Selenomethionine (SeMet) 200 μg/day
Number of subjects: 69
Study 22775364 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 202
Study 22775364 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 202
Study 19106728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist contact with the patient via telephone
Number of subjects: 3048
Study 19106728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist contact with the patient's prescribing physician via facsimile
Number of subjects: 3048
Study 19106728 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3048
Study 17895968 — intervention group
Group type: COMPARATOR
Intervention: CytoMax (C)
Number of subjects: 6
Study 17895968 — intervention group
Group type: COMPARATOR
Intervention: Leading sports drink (G)
Number of subjects: 6
Study 15077100 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 30
Study 15077100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 30
Study 15077100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12356654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 50
Study 12356654 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 9272335 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 10271
Study 9272335 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 10271
Study 9272335 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 10271
Study 8220939 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 400-800 micrograms daily
Number of subjects: 301
Study 8220939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301
Study 3806169 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant methotrexate (MTX) started at 40 mg/m2 and escalated by 10 mg/m2 weekly, with four doses preoperatively, four doses postoperatively before radiation therapy, and eight doses post-radiation therapy.
Number of subjects: 55
Study 3806169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant MTX)
Number of subjects: 55
Study 31138085 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL levels (measured using Single Molecule Array technology)
Number of subjects: 363
Study 31138085 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL levels incorporated into predictive score
Number of subjects: 363
Study 31138085 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of serum NfL
Number of subjects: 363
Study 31138085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk factors
Number of subjects: 363
Study 29318342 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus group‐CBT (17 group sessions)
Number of subjects: 158
Study 29318342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study 26645932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud-based diabetes management program
Number of subjects: 40
Study 24191893 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/day probucol plus 160 mg/day valsartan
Number of subjects: 69
Study 24191893 — intervention group
Group type: COMPARATOR
Intervention: 160 mg/day valsartan
Number of subjects: 69
Study 22812414 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 202
Study 22812414 — intervention group
Group type: COMPARATOR
Intervention: Control (CsA)
Number of subjects: 202
Study 20601912 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with multipurpose solutions
Number of subjects: 0
Study 17664467 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (DCF)
Number of subjects: 445
Study 17664467 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (CF)
Number of subjects: 445
Study 16287499 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 0
Study 16287499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 0
Study 16287499 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 12946081 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual‐assisted cognitive behaviour therapy (MACT)
Number of subjects: 480
Study 12946081 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480
Study 12946081 — intervention group
Group type: EXPERIMENTAL
Intervention: MACT
Number of subjects: 480
Study 11916603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atropine administration
Number of subjects: 120
Study 11916603 — intervention group
Group type: COMPARATOR
Intervention: Conventional atropine administration
Number of subjects: 120
Study 9160597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 106
Study 9160597 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Index (ASI)
Number of subjects: 106
Study 9160597 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 106
Study 1303775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec 10 mg/day)
Number of subjects: 14
Study 2864486 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg zinc per day as zinc acetate
Number of subjects: 32
Study 2864486 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation (control group)
Number of subjects: 32
Study 3623260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (375 mg/day) and vitamin D (1,200 IU/day) supplementation
Number of subjects: 200
Study 3623260 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 200
Study 3623260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 200
Study 31473464 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 56
Study 28987529 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized percutaneous needle electrolysis (PNE) protocol for AWS
Number of subjects: 100
Study 28987529 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy intervention for AWS
Number of subjects: 100
Study 28987529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PNE and physiotherapy)
Number of subjects: 100
Study 25327635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum (HG) patients
Number of subjects: 80
Study 25327635 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control)
Number of subjects: 80
Study 23151774 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 23151774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21519085 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific preoperative information on the procedure and written instructions on postoperative care (n=28)
Number of subjects: 55
Study 21519085 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative information and verbal instructions on postoperative care (n=27)
Number of subjects: 55
Study 19236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (Eso20)
Number of subjects: 77
Study 19236727 — intervention group
Group type: COMPARATOR
Intervention: Pectin‐based raft‐forming agent (PRA)
Number of subjects: 77
Study 16434738 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol 6.88 g/day (G3)
Number of subjects: 132
Study 16434738 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol 10.32 g/day (G4)
Number of subjects: 132
Study 16434738 — intervention group
Group type: COMPARATOR
Intervention: Control (sorbitol/maltitol) (G1)
Number of subjects: 132
Study 15333426 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suctioning (CS) system (TrachCare)
Number of subjects: 24
Study 15333426 — intervention group
Group type: COMPARATOR
Intervention: Open suctioning (OS) system
Number of subjects: 24
Study 10679534 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (asthma education and optimisation of drug therapy)
Number of subjects: 689
Study 10679534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 689
Study 9333148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with recombinant HIV-1 gp160
Number of subjects: 0
Study 9333148 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone or in combination with the immunogen
Number of subjects: 0
Study 9333148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with gp160
Number of subjects: 0
Study 9333148 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 8222665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid taken 1/2 hour before OC intake
Number of subjects: 37
Study 8222665 — intervention group
Group type: COMPARATOR
Intervention: Combination monophasic oral contraceptive without ascorbic acid
Number of subjects: 37
Study 2429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 4 mg/kg, plus placebo
Number of subjects: 24
Study 2429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 0.1 mg/kg, plus placebo
Number of subjects: 24
Study 2429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus chlorpheniramine
Number of subjects: 24
Study 2429800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31616979 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Reconstruction of Vesicourethral Support (ARVUS) technique
Number of subjects: 0
Study 31616979 — intervention group
Group type: COMPARATOR
Intervention: Nerve-sparing approach (not specified if unilateral or bilateral)
Number of subjects: 0
Study 31616979 — intervention group
Group type: COMPARATOR
Intervention: Time after surgery
Number of subjects: 0
Study 31616979 — intervention group
Group type: COMPARATOR
Intervention: Nerve-sparing status
Number of subjects: 0
Study 29727369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-illuminance blue light therapy
Number of subjects: 0
Study 29727369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus high-illuminance blue light
Number of subjects: 0
Study 29727369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright blue light
Number of subjects: 0
Study 29727369 — intervention group
Group type: COMPARATOR
Intervention: Bright red or ambient white fluorescent light
Number of subjects: 0
Study 27480676 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring (self-reported by adolescents)
Number of subjects: 87
Study 27480676 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring (parent-reported)
Number of subjects: 87
Study 25270585 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 317
Study 25270585 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 317
Study 25270585 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 317
Study 22689870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring and skills group intervention
Number of subjects: 110
Study 20214175 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1%/benzoyl peroxide 5% gel (BPO/C)
Number of subjects: 0
Study 20214175 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate 1.2%/tretinoin 0.025% gel (T/C)
Number of subjects: 0
Study 18023130 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based motivational counselling by trained practice nurses
Number of subjects: 1378
Study 18023130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1378
Study 15953490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 421
Study 15953490 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 421
Study 31930830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,4-D (0, 1, 2) ppm with BAP (0, 0.5, 1) ppm in light and dark conditions
Number of subjects: 0
Study 31930830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 2,4-D and BAP)
Number of subjects: 0
Study 10626316 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor-based cognitive behavioral therapy
Number of subjects: 0
Study 10626316 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback intervention
Number of subjects: 0
Study 10626316 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 0
Study 10626316 — intervention group
Group type: COMPARATOR
Intervention: Refusers of therapy
Number of subjects: 0
Study 10626316 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients
Number of subjects: 0
Study 7738941 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 496
Study 7738941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 2076342 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system of scopolamine (TTS-S)
Number of subjects: 130
Study 2076342 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo (TD-P)
Number of subjects: 130
Study 7288807 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-isomer of tranylcypromine at doses below 3 mg/day
Number of subjects: 0
Study 7288807 — intervention group
Group type: COMPARATOR
Intervention: (-)-isomer of tranylcypromine
Number of subjects: 0
Study 30125510 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier progression-free survival data from the CLEOPATRA trial
Number of subjects: 0